---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-001448"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:54:26.515393+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Celldex Q4 net loss $20.1M; CDX-0159 Phase 2 urticaria studies to start Q2 2022

## Summary
- Net loss of $20.1M ($0.43 diluted EPS) for Q4 2021; full year net loss $70.5M ($1.64 EPS).
- Cash and marketable securities $408.3M as of Dec 31, 2021; provides runway through 2025.
- CDX-0159 Phase 1b CSU data expected July 2022; Phase 2 studies in CSU and CIndU to initiate Q2 2022.
- Plans to expand CDX-0159 development into eosinophilic esophagitis (EoE) with Phase 2 trial in Q4 2022.
- Subcutaneous formulation of CDX-0159 well tolerated; supports planned Phase 2 doses of 75mg, 150mg, 300mg.

## SEC filing metadata
- accession: 0001171843-22-001448
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184322001448/0001171843-22-001448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184322001448/f8k_022822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-001448
- JSON: https://secwatch.observer/filing/0001171843-22-001448.json
- Plain text: https://secwatch.observer/filing/0001171843-22-001448.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.